4263 Stock Overview
Develops and sells therapeutic applications in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
SUSMED,Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥655.00 |
| 52 Week High | JP¥706.00 |
| 52 Week Low | JP¥375.00 |
| Beta | 1.51 |
| 1 Month Change | 0.61% |
| 3 Month Change | 7.55% |
| 1 Year Change | 8.26% |
| 3 Year Change | -35.66% |
| 5 Year Change | n/a |
| Change since IPO | -64.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4263 | JP Healthcare Services | JP Market | |
|---|---|---|---|
| 7D | 4.1% | 17.4% | 1.4% |
| 1Y | 8.3% | -14.1% | 4.3% |
Return vs Industry: 4263 exceeded the JP Healthcare Services industry which returned -14.1% over the past year.
Return vs Market: 4263 exceeded the JP Market which returned 4.3% over the past year.
Price Volatility
| 4263 volatility | |
|---|---|
| 4263 Average Weekly Movement | 5.1% |
| Healthcare Services Industry Average Movement | 5.5% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in JP Market | 7.4% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4263 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4263's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 39 | Taro Ueno | www.susmed.co.jp |
SUSMED,Inc. develops and sells therapeutic applications in Japan. It develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease.
SUSMED,Inc. Fundamentals Summary
| 4263 fundamental statistics | |
|---|---|
| Market cap | JP¥11.01b |
| Earnings (TTM) | -JP¥579.00m |
| Revenue (TTM) | JP¥150.00m |
73.4x
P/S Ratio-19.0x
P/E RatioIs 4263 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4263 income statement (TTM) | |
|---|---|
| Revenue | JP¥150.00m |
| Cost of Revenue | JP¥13.00m |
| Gross Profit | JP¥137.00m |
| Other Expenses | JP¥716.00m |
| Earnings | -JP¥579.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -34.44 |
| Gross Margin | 91.33% |
| Net Profit Margin | -386.00% |
| Debt/Equity Ratio | 0% |
How did 4263 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/19 20:13 |
| End of Day Share Price | 2025/02/19 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SUSMED,Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.